{"organizations": [], "uuid": "b29245407310c0dff692d1a2ff9a1db8ca5b7cae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180313&t=2&i=1240425371&w=1200&r=LYNXNPEE2C0QL", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-roche-agm/roche-ceo-says-new-drugs-will-offset-biosimilar-incursions-idUKKCN1GP1BE", "country": "US", "domain_rank": 408, "title": "Roche CEO says new drugs will offset biosimilar incursions", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-13T12:53:00.000+02:00", "replies_count": 0, "uuid": "b29245407310c0dff692d1a2ff9a1db8ca5b7cae"}, "author": "", "url": "https://uk.reuters.com/article/us-roche-agm/roche-ceo-says-new-drugs-will-offset-biosimilar-incursions-idUKKCN1GP1BE", "ord_in_thread": 0, "title": "Roche CEO says new drugs will offset biosimilar incursions", "locations": [], "entities": {"persons": [{"name": "reu", "sentiment": "negative"}, {"name": "john miller", "sentiment": "none"}, {"name": "reuters/arnd wiegmann schwan", "sentiment": "none"}, {"name": "severin schwan", "sentiment": "none"}], "locations": [{"name": "basel", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "roche ceo", "sentiment": "negative"}, {"name": "roche", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 13, 2018 / 10:54 AM / a day ago Roche CEO says new drugs will offset biosimilar incursions Reuters Staff 1 Min Read ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals’ copies through its new medicines, Chief Executive Severin Schwan said on Tuesday. CEO Severin Schwan of Swiss drugmaker Roche addresses the company's annual news conference in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann Schwan’s outlook, delivered to shareholders at the company’s annual general meeting in Basel, confirms Roche’s previous guidance that 2018 sales will be flat or grow by a low-single-digit percentage compared to last year, amid incursions from so-called biosimilar drugs. Reporting by John Miller", "external_links": [], "published": "2018-03-13T12:53:00.000+02:00", "crawled": "2018-03-14T18:50:05.009+02:00", "highlightTitle": ""}